Related Articles
A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib
Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation
5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade